{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:31:32Z","timestamp":1790245892478,"version":"4.1.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/jcp.0b013e318253a186","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T09:43:35Z","timestamp":1335519815000},"page":"362-375","source":"Crossref","is-referenced-by-count":68,"title":["Behavioral Adverse Effects of Antiepileptic Drugs in Epilepsy"],"prefix":"10.1097","volume":"32","author":[{"given":"Clare Margaret","family":"Eddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh Edward","family":"Rickards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Eugenio","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.seizure.2008.11.006","article-title":". The impact of side effects on long term retention in three new antiepileptic drugs.","volume":"18","author":"Bootsma","year":"2009","journal-title":"Seizure"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":". The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1185\/146300905X75361","article-title":"Phenobarbital for childhood epilepsy: systematic review.","volume":"7","author":"Pal","year":"2006","journal-title":"Paediatr Perinat Drug Ther"},{"issue":"6","key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children.","volume":"29","author":"Herranz","year":"1988","journal-title":"Epilepsia"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jnnp.58.1.44","article-title":". Phenobarbitone, phenytoin, carbamazepine, and sodium valproate for newly diagnosed adult epilepsy: a randomized comparative monotherapy trial.","volume":"58","author":"Heller","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":". The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassified epilepsy: an unblinded, randomized clinical trial.","volume":"365","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":". The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.30.1.31","article-title":"Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a 6-month trial.","volume":"30","author":"Sherard","year":"1980","journal-title":"Neurology"},{"issue":"8","key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1980.03310080019016","article-title":"Valproic acid therapy in childhood epilepsy.","volume":"244","author":"Coulter","year":"1980","journal-title":"J Am Med Assoc"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/NDT.S5903","article-title":"Bateh Ael-A, Hamed SA, et al.. Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy.","volume":"5","author":"Shehata","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9172","key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(98)10531-7","article-title":"Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre, randomized, double-blind study.","volume":"354","author":"Chadwick","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archneur.56.5.605","article-title":"Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children.","volume":"56","author":"Zamponi","year":"1999","journal-title":"Arch Neurol"},{"issue":"4","key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1017\/S0317167100034296","article-title":"Seizure exacerbation and developmental regression with carbamazepine.","volume":"25","author":"Prasad","year":"1998","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/088307389901401106","article-title":"Cognitive and behavioral effects of carbamazepine in children: data from benign Rolandic epilepsy.","volume":"14","author":"Seidel","year":"1999","journal-title":"J Child Neurol"},{"issue":"2","key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/seiz.2000.0382","article-title":"Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.","volume":"9","author":"Guberman","year":"2000","journal-title":"Seizure"},{"issue":"3","key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1059-1311(05)80188-8","article-title":"Vigabatrin use in 72 patients with drug-resistant epilepsy.","volume":"3","author":"Buchanan","year":"1994","journal-title":"Seizure"},{"issue":"5","key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0887-8994(99)00098-3","article-title":"Efficacy of lamotrigine and vigabatrin in drug-resistant epilepsies of childhood.","volume":"21","author":"Dimova","year":"1999","journal-title":"Pediatr Neurol"},{"issue":"3","key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0920-1211(95)00022-3","article-title":"Retrospective study of vigabatrin and psychiatric behavioural disturbances.","volume":"21","author":"Wong","year":"1995","journal-title":"Epilepsy Res"},{"issue":"3","key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1017\/S0317167100030651","article-title":"Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood.","volume":"17","author":"Keene","year":"1990","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"R42-11-20210128","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00002826-199408000-00004","article-title":"Aggression in children treated with clobazam for epilepsy.","volume":"17","author":"Sheth","year":"1994","journal-title":"Clin Neuropharmacol"},{"issue":"7","key":"R43-11-20210128","first-page":"622","article-title":"Clobazam for the treatment of intractable childhood epilepsy.","volume":"21","author":"Jan","year":"2000","journal-title":"Saudi Med J"},{"issue":"3","key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/08830738050200030801","article-title":"Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center.","volume":"20","author":"Kim","year":"2005","journal-title":"J Child Neurol"},{"issue":"suppl 5","key":"R49-11-20210128","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1111\/j.1528-1157.1999.tb00921.x","article-title":"Gabapentin.","volume":"40","author":"Morris","year":"1999","journal-title":"Epilepsia"},{"issue":"5","key":"R51-11-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pediatrneurol.2008.12.016","article-title":"Pregabalin: preliminary experience in intractable childhood epilepsy.","volume":"40","author":"Jan","year":"2009","journal-title":"Pediatr Neurol"},{"issue":"3","key":"R52-11-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.yebeh.2006.07.011","article-title":"Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study.","volume":"9","author":"Ciesielski","year":"2006","journal-title":"Epilepsy Behav"},{"issue":"3","key":"R53-11-20210128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.yebeh.2005.07.006","article-title":"A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life.","volume":"7","author":"Kerr","year":"2005","journal-title":"Epilepsy Behav"},{"key":"R54-11-20210128","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":". A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group.","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"R55-11-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1528-1157.1996.tb00649.x","article-title":". Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy.","volume":"37","author":"Tassinari","year":"1996","journal-title":"Epilepsia"},{"key":"R56-11-20210128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(96)00029-0","article-title":". Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy.","volume":"25","author":"Sharief","year":"1996","journal-title":"Epilepsy Res"},{"issue":"2","key":"R59-11-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/seiz.2000.0387","article-title":"Efficacy and tolerability of topiramate in childhood and adolescent epilepsy: a clinical experience.","volume":"9","author":"Mohamed","year":"2000","journal-title":"Seizure"},{"issue":"4","key":"R65-11-20210128","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1525-5050(03)00145-8","article-title":"The importance of being seizure free: topiramate and psychopathology in epilepsy.","volume":"4","author":"Mula","year":"2003","journal-title":"Epilepsy Behav"},{"issue":"1","key":"R68-11-20210128","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/seiz.1998.0212","article-title":"Topiramate for intractable childhood epilepsy.","volume":"8","author":"Moreland","year":"1999","journal-title":"Seizure"},{"issue":"4","key":"R72-11-20210128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00044011-199611040-00004","article-title":"Three-year efficacy and tolerability of add-on lamotrigine in treatment-resistant epileptic children.","volume":"11","author":"Herranz","year":"1996","journal-title":"Clin Drug Invest"},{"issue":"5","key":"R74-11-20210128","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1998.tb01411.x","article-title":"The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study.","volume":"39","author":"Ericksson","year":"1998","journal-title":"Epilepsia"},{"issue":"2","key":"R75-11-20210128","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0883073809336874","article-title":"Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy.","volume":"25","author":"Cardenas","year":"2010","journal-title":"J Child Neurol"},{"issue":"3","key":"R78-11-20210128","first-page":"359","article-title":"Lamotrigine as an add-on therapy in intractable paediatric epilepsythe Kuala Lumpur Hospital experience.","volume":"56","author":"Vigneswari","year":"2001","journal-title":"Med J Malaysia"},{"issue":"2","key":"R86-11-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerance and efficacy of 2 oral doses of levetiracetam, 2000 mg daily and 4000 mg daily without titration, in patients with refractory epilepsy.","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"issue":"5","key":"R91-11-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1177\/0883073807309781","article-title":"Efficacy of levetiracetam in children with epilepsy younger than 2 years of age.","volume":"23","author":"Krief","year":"2008","journal-title":"J Child Neurol"},{"issue":"1","key":"R92-11-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eplepsyres.2010.06.009","article-title":"Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy.","volume":"91","author":"Obeid","year":"2010","journal-title":"Epilepsy Res"},{"issue":"6","key":"R94-11-20210128","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2007.01003.x","article-title":"Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.","volume":"48","author":"Perry","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"R100-11-20210128","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2004.10.004","article-title":"Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial.","volume":"14","author":"Lagae","year":"2005","journal-title":"Seizure"},{"issue":"6","key":"R103-11-20210128","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.yebeh.2004.07.009","article-title":"Levetiracetam for people with mental retardation and refractory epilepsy.","volume":"5","author":"Kelly","year":"2004","journal-title":"Epilepsy Behav"},{"issue":"3","key":"R105-11-20210128","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1155\/2007\/832769","article-title":"Comparison of motor activity and sleep in patients with complex partial seizures on levetiracetam treatment and a group of healthy subjects.","volume":"18","author":"Yilmaz","year":"2007","journal-title":"Behav Neurol"},{"issue":"3","key":"R109-11-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1059-1311(02)00251-0","article-title":"Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.","volume":"12","author":"Ben-Menachem","year":"2003","journal-title":"Seizure"},{"issue":"1","key":"R112-11-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(03)00111-0","article-title":"Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam.","volume":"13","author":"Mula","year":"2004","journal-title":"Seizure"},{"issue":"suppl 2","key":"R116-11-20210128","first-page":"53","article-title":"Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders.","volume":"53","author":"Ketter","year":"1999","journal-title":"Neurology"},{"key":"R117-11-20210128","first-page":"121","article-title":"Some clinical EEG correlations in epileptic psychoses (twilight states).","volume":"5","author":"Landolt","year":"1953","journal-title":"EEG Clin Neurophysiol"},{"key":"R120-11-20210128","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1525-5050(02)00052-5","article-title":". Forced normalization at the interface between epilepsy and psychiatry.","volume":"3","author":"Krishnamoorthy","year":"2002","journal-title":"Epilepsy Behav"},{"issue":"7","key":"R121-11-20210128","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/seiz.2000.0446","article-title":"Validation of the Side Effect and Life Satisfaction (SEALS) inventory.","volume":"9","author":"Gillham","year":"2000","journal-title":"Seizure"},{"key":"R123-11-20210128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/DHPS.S13070","article-title":"Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence.","volume":"3","author":"Mula","year":"2011","journal-title":"Drug Healthc Patient Saf"},{"key":"R124-11-20210128","first-page":"978","article-title":"The FDA alert on suicidality and antiepileptic drugs: fire or false alarm Epilepsia.","volume":"50","author":"Hesdorffer","year":"2009","journal-title":""},{"key":"R125-11-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/DHPS.S13225","article-title":"Antiepileptic drugs and suicidality.","volume":"2","author":"Britton","year":"2010","journal-title":"Drug Healthc Patient Saf"},{"key":"R127-11-20210128","first-page":"1","article-title":". Suicide-related behaviors in older patients with new anti-epileptic drug use: data from the VA hospital system.","volume":"8","author":"van Cott","year":"2010","journal-title":"BMC Med"},{"key":"R128-11-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0924-9338(97)83297-X","article-title":". The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability.","volume":"12","author":"Sheehan","year":"1997","journal-title":"Eur Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318253a186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:59:48Z","timestamp":1620957588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201206000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318253a186","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}